News

Inflammatory Th17 Cells Seen to Trigger Obsessive Compulsive Disorder in MS Mouse Model

The pro-inflammatory Th17 cells that characterize multiple sclerosis (MS) may also underlie symptoms of obsessive-compulsive disorder (OCD), results of a mouse study show. The study, ā€œAuto-Reactive Th17-Cells Trigger Obsessive-Compulsive-Disorder Like Behavior in Mice With Experimental Autoimmune Encephalomyelitis,ā€ was published in the journalĀ Frontiers in Immunology. “For the first time,…

Embracing Carers Expanding Global Reach to Brazil, Possibly China

To more widely recognize and help those caring for people with multiple sclerosis (MS) and other chronic diseases, Merck KGaAĀ (known in the U.S. and Canada as EMD Serono) is expanding its global Embracing Carers program to include Brazil and possibly China. ā€œCaregivers are a hidden pillar within the…

Accelerated Cure Project Teams with RealTalk MS for Weekly Podcasts

To increase the exchange of research information and goings-on with the patient community, the Accelerated Cure Project (ACP) for Multiple Sclerosis (MS) has teamed with RealTalk MS, a weekly podcast for those affected by the disease. Specifically, ACP will share ongoing results of its research initiative, iConquerMS.Ā In…

Denali and Sanofi Partner to Develop Potential Treatments for MS, Other Neurological Disorders

Denali Therapeutics andĀ SanofiĀ will collaborateĀ to develop a compound called DNL747 that may treatĀ multiple sclerosis (MS) and other neurodegenerative disorders. The companies will also jointly work on the development of a separate possible therapy, DNL758, for systemic inflammatory diseases such as rheumatoid arthritis and psoriasis. Both DNL747 and DNL758…

Salt-rich Diet Appears to Trigger Inflammation and Promote Autoimmune Disease by Impact on T-cells, Study Reports

Researchers at Yale uncovered a way that high-salt diets may trigger inflammation and possibly contribute to the development of autoimmune diseases such as multiple sclerosis (MS). Their study, “Activated Ī²-catenin in Foxp3+ regulatory T cells links inflammatory environments to autoimmunity,” was recently published in the journalĀ Nature…

First Descents Expands Adventure Program to Include Young Adults With MS

Following its well-received pilot program,Ā First Descents has broadened its adventure-based program for cancer patients to include young adults with multiple sclerosis (MS). For 17 years, the non-profit has specialized in free outdoor activities, community building, and skills development for young adults with cancer. In September,Ā First Descents conducted a successful…

Stanford Researchers Open Medical Cannabis Company with Oral Therapy for MS Pain, Spasticity as Initial Goal

A new medical cannabis company calledĀ Katexco PharmaceuticalsĀ aims to develop oral therapies that harness the brain’s endocannabinoid and nicotine receptors to treat inflammatory diseases such as multiple sclerosis. Co-founded by two Stanford University researchers ā€” Jonathan Rothbard, PhD, and Lawrence Steinman, MD ā€” Katexco will leverage their expertise…

Infection with Common Herpes Virus Speeds MS-like Disease Onset and Progression in Primate Model, Study Reports

Infection with theĀ most common member of the herpes virus family, called HHV-6, may pass unnoticed and without symptoms, but the very act of being infected significantly accelerated the development and progression of aĀ multiple sclerosis-like disease in nonhuman primates, a study reports. Its findings support the role of viral infection in…

Stem Cells from MS, Parkinson’s Patients Voyaging to Space Station to Study Disease Impact on Brain in Microgravity

Stem cellsĀ from patients with Parkinsonā€™s diseaseĀ and primary progressive multiple sclerosis (PPMS) are soon to voyage into space, and be brought aboard the International Space Station so cell-to-cell interactions in these neurodegenerative diseases can be studied withoutĀ gravitational forces acting on them. This research project, proposed to launch in May…

#ECTRIMS2018 – Ocrevus Used Early in MS Course Key to Slowing Disability, Genentech Director Says

Treating patients withĀ primary progressive or relapsing multiple sclerosis (MS) early with Ocrevus (ocrelizumab) is key to slowing disease progression, according to Hideki Garren, global head of Multiple Sclerosis and Neuroimmunology at Genentech. In an interview withĀ Multiple Sclerosis NewsĀ TodayĀ at the recentĀ 34thĀ congress of the European Committee for Treatment…